Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Amneal Pharmaceuticals, Inc.

AMRX ✗ NOT COMPLIANT ☆ Track — members

NASDAQ · Healthcare · Pharmaceuticals ·

USA Mid Cap Analyst: BUY

Last Close

$17.01

▲ +0.83%

Market Cap $5.92B · Vol 400.92K

Key Metrics

P/E Ratio

35.50

FWD: 14.94

Market Cap

$5.92B

Mid Cap

Div Yield

N/A

EPS Growth

+23.86%

YoY

RSI (14)

36.02

Momentum

Beta

1.24

vs Market

52W High

$19.26

11.68% below

52W Low

$9.50

79.05% above

Volume

400.92K

Avg 654.35K

P/B

N/A

Price-to-book

ROE

-298.24%

Return on equity

Free Float

44.36%

Public shares

Shariah Compliance8 STANDARDS

✗ Amneal Pharmaceuticals, Inc. (AMRX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does AMRX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-4.81%

-0.53%

+4.10%

+33.83%

YTD

+35.00%

+68.58%

+325.25%

+232.23%

Financials & Valuation

TTM · Annual

Total Revenue	$3.02B
Net Income	$127.93M
Revenue Growth (YoY)	+9.89%
Gross Margin	36.88%
Operating Margin	13.18%
Net Profit Margin	4.24%
ROE	-298.24%
ROA · ROIC	3.88% · 11.43%

P/E Ratio	35.50
Forward P/E (FY1)	14.94
PEG Ratio	0.36
P/S	1.36
P/B	N/A
P/FCF	18.14
EPS Growth	+23.86%
Outstanding Shares	348.30M

Technical Indicators

50-Day SMA	$17.75
200-Day SMA	$14.48
RSI (14)	36.02
Beta	1.24
52-Week High	$19.26
52-Week Low	$9.50

Volume Today	400.92K
Avg Daily Volume (30D)	654.35K
Relative Volume	0.61x
Volatility (10D)	26.93
Volatility (30D)	31.14
Free Float	44.36%

Analyst Consensus

BUY

Current Price $17.01

Mean Target $20.87

52W Low$9.50 52W High$19.26

Current

Target

$9.50 $19.26

Current Analyst target

+22.69% upside potential · 7 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00462PGH9

ISINUS03168L1052

CountryUSA

Sub-IndustryPharmaceuticals (NEC)

Earnings DateOct 28, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Company -0.65% JNJ Johnson & Johnson -0.29% ABBV AbbVie Inc. +0.83% NVS Novartis AG -0.23% NOVN.S Novartis AG -0.09%

Company Profile

Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.